Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of 4CMenB given with routine infant vaccines in healthy infants in Taiwan
2014-005568-14Phase 3
- Sponsor
- Novartis
- Start
- Jun 2015
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meningococcal group B vaccine in meningococcal disease (2 arms), sponsored by Novartis. Primary endpoints: Infant post-primary immunogenicity and Toddler post-booster immunogenicity.
02
Drugs
meningococcal group B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2014-005568-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005568-14.